Abbott's ABT growth is backed by strong improvement in global Core Laboratory Diagnostics sales, led by continued strong ...

2024 Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.

Abbott Laboratories maintains a fortress-like balance ... Chairman and CEO Robert Ford pointed to recent large account wins in its core labs business. This should help the Diagnostics segment ...

Core Laboratory Diagnostics segment sales, also excluding Covid-19 testing, rose by 0.1% on a reported basis and 4.5% organically, driven by the growing adoption of Abbott's Alinity diagnostics ...

Welcome to Abbott's Third Quarter 2024 Earnings ... Moving to Diagnostics. Our sales in Core Laboratory Diagnostics increased 4.5% excluding COVID testing sales. Growth in Core Lab was driven ...

Core Laboratory Diagnostics Sales Growth ... Fourth Quarter EPS Guidance: $1.31 to $1.37. Abbott Laboratories (NYSE:ABT) reported strong organic sales growth of over 8%, excluding COVID testing ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...